Skip to research
Margin Monkey THEMARGINMONKEY Start my free trialTry free

Integra Lifesciences (IART) stock in plain English

Free brief · no signupStart here
IARTPublished Nov 18, 2026
Integra Lifesciences Holdings Corp
Healthcare · Medical Devices
Manufactures regenerative tissue technologies, electrosurgical devices, and surgical instruments.
Assets:
Boston manufacturing siteUpgraded facility dedicated to regenerative tissue and collagen implant production.
4,500 employeesGlobal workforce across manufacturing, commercial, and research operations.
Codman specialty surgicalNeurosurgery portfolio covering advanced instrumentation and brain monitoring systems.
Locked assetIn the full report
Rated Nov 19, 2026

Every company we rate gets Strong Buy, Buy, Buy with Caution, Hold or Sell. Members see the rating for this company and the five scores behind it.

46
OPS ScoreOperating finances
Latest quote
-2.24%$13.55
$1.05B
82.4×
$1.65B

Change shown by the quote provider. Data may be delayed.

Financial statements, in plain wordsSales, profit, debt and cash, year by year
Published Nov 18, 2026Quotes updated Nov 20, 04:05 UTCOPS Score, TMM Score and the rating are research summaries, not advice or forecasts.
That was IART. The desk has 1,900+ more companies.Each one comes with its scores, its flags and the sources behind them.
7 days free · No card

What does Integra Lifesciences (IART) do?

Integra Lifesciences Holdings Corp (IART) is a U.S.-listed company in Healthcare (Medical Devices). What it does: Manufactures regenerative tissue technologies, electrosurgical devices, and surgical instruments. Produces collagen-based implants and specialized surgical tools used in brain surgery and wound repair. It is worth $1.05B on the market and sold $1.65B over the last year.

Market cap
$1.05B
P/E ratio
82.4×
Annual sales
$1.65B
Sector
Healthcare
Industry
Medical Devices
Brief updated
Nov 18, 2026

Brands and businesses behind IART

  • Codman: Provides neurosurgical access tools, micro-instruments, and intracranial pressure monitors sold directly to hospital operating rooms.
  • DuraGen: Supplies collagen dural graft matrices that seal brain tissue and prevent cerebrospinal fluid leaks after head surgeries.
  • CUSA: Markets ultrasonic tissue ablation systems used by neurosurgeons to selectively remove soft tissue tumors.
  • Mayfield: Sells rigid skull clamp systems that hold a patient head securely in place during delicate brain surgery.
  • SurgiMend: Manufactures bovine collagen matrices used to reinforce soft tissue during complex plastic and reconstructive operations.

IART’s flags, in plain English

Each flag is a number from Integra Lifesciences’ reports to the SEC or from market data, with the reason it matters. This brief was updated on Nov 18, 2026.

Stupid Cash

Can pay this year's bills 3.6 times over. Cash in the bank covers a long stretch of running costs. The company can fund itself without borrowing or selling new shares.

Cheap on Cash Flow

Priced at 12.3 times the cash it generates each year. The share price is low compared with the cash the business actually brings in, and cash is harder to dress up than profit.

Wide Gross Margin

Gross margin of 54.9% after the cost of making its products. There is a large gap between what its products cost to make and what they sell for, and that gap pays for everything else.

Debt Is Driving

Heavy debt, 188% of shareholder equity. The company owes a lot compared with what it earns. Lenders get paid before shareholders, which leaves management fewer options in a weak year.

1 more green flag and 2 more risk notes open with the free trial. Try it free for 7 days.

Questions about IART

How big is Integra Lifesciences?

Integra Lifesciences’ market cap is $1.05B: what all of its shares are worth together at today’s price. Its annual sales (revenue) are $1.65B: what customers paid the company over the last year, before any costs.

What is IART’s P/E ratio?

IART’s P/E ratio is 82.4×. Investors pay about 82.4 dollars for each dollar of the company’s yearly profit. A low number can mean a bargain or a problem, so read it next to the flags.

What could go wrong with IART?

Manufacturing quality compliance issues at key production sites have previously halted operations and triggered costly product recalls. That is one risk on Integra Lifesciences’ card. Its first risk flag is Debt Is Driving, explained above. The card holds 2 more risk notes for trial accounts. A flag reads what the company reported. It does not predict the price.

Where do these numbers come from?

From Integra Lifesciences’ own reports to the SEC (annual and quarterly) and from market data. Every company runs through the same scoring formula, and a reviewer spot-checks cards against the source data. IART’s filings on SEC.gov. The Margin Monkey is research, not advice.

Your first 7 days are free.Search all 1,900+ companies and open every card. Members also get the ratings, Picks and the TMM Score.
7 days free · No card